Advertisement
LIEN vs SHPH
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LIEN is a Hold and SHPH is a Hold.
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
LIEN’s FA Score shows that 1 FA rating(s) are green whileSHPH’s FA Score has 0 green FA rating(s).
- LIEN’s FA Score: 1 green, 4 red.
- SHPH’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
LIEN’s TA Score shows that 4 TA indicator(s) are bullish while SHPH’s TA Score has 1 bullish TA indicator(s).
- LIEN’s TA Score: 4 bullish, 5 bearish.
- SHPH’s TA Score: 1 bullish, 6 bearish.
Price Growth
LIEN (@Investment Managers) experienced а +7.11% price change this week, while SHPH (@Pharmaceuticals: Generic) price change was -2.92% for the same time period.
The average weekly price growth across all stocks in the @Investment Managers industry was +0.77%. For the same industry, the average monthly price growth was +0.84%, and the average quarterly price growth was +29.70%.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +6.26%. For the same industry, the average monthly price growth was +68.76%, and the average quarterly price growth was +80.82%.
Reported Earning Dates
LIEN is expected to report earnings on Nov 06, 2025.
Industries' Descriptions
@Investment Managers (+0.77% weekly)Investment Managers manage financial assets and other investments of clients. Management includes designing a short- or long-term strategy for buying/holding and selling of portfolio holdings. It can also include tax services and other aspects of financial planning as well. While it is perceived that the industry is faced with growing competition from robo-advisors/digital platforms and passive/ index-tracking funds, many investors still find value in actively managed in-person services that investment management companies often emphasize on. At the same time, many wealth managers are also incorporating digital initiatives/low cost options in addition to their in-person customized services. Their main sources of revenues are fees as a percentage of assets under management, in addition to a certain portion of clients’ gains from asset appreciation. BlackRock, Inc., Blackstone Group Inc and Brookfield Asset Management are some of the major investment management companies.
@Pharmaceuticals: Generic (+6.26% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
| LIEN | SHPH | LIEN / SHPH | |
| Capitalization | 251M | 3.56M | 7,060% |
| EBITDA | N/A | N/A | - |
| Gain YTD | -4.113 | -84.540 | 5% |
| P/E Ratio | 8.15 | N/A | - |
| Revenue | N/A | N/A | - |
| Total Cash | 5.4K | 4.51M | 0% |
| Total Debt | N/A | 1.1M | - |
| LIEN | SHPH | |
|---|---|---|
| RSI ODDS (%) | 4 days ago 65% | N/A |
| Stochastic ODDS (%) | 4 days ago 64% | 4 days ago 83% |
| Momentum ODDS (%) | 4 days ago 50% | 4 days ago 90% |
| MACD ODDS (%) | 4 days ago 64% | 4 days ago 90% |
| TrendWeek ODDS (%) | 4 days ago 51% | 4 days ago 90% |
| TrendMonth ODDS (%) | 4 days ago 50% | 4 days ago 90% |
| Advances ODDS (%) | 4 days ago 50% | N/A |
| Declines ODDS (%) | 12 days ago 62% | 4 days ago 90% |
| BollingerBands ODDS (%) | 4 days ago 64% | 5 days ago 90% |
| Aroon ODDS (%) | 4 days ago 50% | 4 days ago 90% |
Advertisement
LIEN and
Correlation & Price change
A.I.dvisor tells us that LIEN and SHPH have been poorly correlated (+20% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that LIEN and SHPH's prices will move in lockstep.
| Ticker / NAME | Correlation To LIEN | 1D Price Change % | ||
|---|---|---|---|---|
| LIEN | 100% | +5.36% | ||
| SHPH - LIEN | 20% Poorly correlated | -5.14% | ||
| IMCC - LIEN | 13% Poorly correlated | N/A | ||
| OXLCP - LIEN | 13% Poorly correlated | +0.16% | ||
| NTRSO - LIEN | 9% Poorly correlated | -0.07% | ||
| TKNO - LIEN | 8% Poorly correlated | -2.29% | ||
More | ||||
SHPH and
Correlation & Price change
A.I.dvisor tells us that SHPH and LFCR have been poorly correlated (+31% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that SHPH and LFCR's prices will move in lockstep.
| Ticker / NAME | Correlation To SHPH | 1D Price Change % | ||
|---|---|---|---|---|
| SHPH | 100% | -5.14% | ||
| LFCR - SHPH | 31% Poorly correlated | -0.67% | ||
| PLSH - SHPH | 24% Poorly correlated | N/A | ||
| IPSEF - SHPH | 20% Poorly correlated | N/A | ||
| LIEN - SHPH | 20% Poorly correlated | +5.36% | ||
| CTOR - SHPH | 15% Poorly correlated | -1.74% | ||
More | ||||